{"transactions":[{"id":817142,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":53916,"kind":"person","name":"Shiferman Gregory L.","position":1,"cik":"0002041689","reported_name":"Shiferman Gregory L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Common Stock","published_at":"2026-04-03T21:42:56.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of common stock issuable under an aggregate of 50,000 restricted stock units (\"RSUs\") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the \"Plan\"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, April 1, 2026. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001104659-26-039689","document":"tm2611148-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2041689/000110465926039689/tm2611148-2_4seq1.xml","form_type":"4"}},{"id":943428,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":53916,"kind":"person","name":"Shiferman Gregory L.","position":1,"cik":"0002041689","reported_name":"Shiferman Gregory L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-08T23:10:46.000Z","date":"2026-01-06","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock option was granted pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The vesting commencement date of the option is the grant date. The option vests over four years, with 1/4th of the shares of common stock underlying the option vesting upon the one-year anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service as an employee."}],"balance_after":100000,"derivative":{"exercise_price":4.02,"expiration_date":"2036-01-06","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-26-002225","document":"tm262553-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2041689/000110465926002225/tm262553-2_4seq1.xml","form_type":"4"}},{"id":1078510,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":53916,"kind":"person","name":"Shiferman Gregory L.","position":1,"cik":"0002041689","reported_name":"Shiferman Gregory L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-31T15:22:20.000Z","date":"2025-07-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a \"Company Option\") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a \"Company Option\") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":6.97,"expiration_date":"2035-01-16","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0000950170-25-100643","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2041689/000095017025100643/ownership.xml","form_type":"4"}},{"id":1078509,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":53916,"kind":"person","name":"Shiferman Gregory L.","position":1,"cik":"0002041689","reported_name":"Shiferman Gregory L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-31T15:22:20.000Z","date":"2025-07-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a \"Company Option\") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a \"Company Option\") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":6.05,"expiration_date":"2034-11-01","underlying":"Common Stock","underlying_shares":10500},"source":{"system":"sec-edgar","filing":"0000950170-25-100643","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2041689/000095017025100643/ownership.xml","form_type":"4"}},{"id":1078508,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":53916,"kind":"person","name":"Shiferman Gregory L.","position":1,"cik":"0002041689","reported_name":"Shiferman Gregory L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-07-31T15:22:20.000Z","date":"2025-07-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23735,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person. Each RSU represented a contingent right to receive one Share upon vesting of the RSU (a \"Company RSU\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment equal to the product of the Closing Amount multiplied by the number of Shares subject to such Company RSU, without interest and subject to the withholding of applicable taxes, plus (ii) one CVR for each Share subject to such Company RSU immediately prior to the Effective Time."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-100643","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2041689/000095017025100643/ownership.xml","form_type":"4"}},{"id":1078507,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":53916,"kind":"person","name":"Shiferman Gregory L.","position":1,"cik":"0002041689","reported_name":"Shiferman Gregory L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-07-31T15:22:20.000Z","date":"2025-07-31","kind":"other","planned":false,"acquired":false,"shares":7215,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the \"Issuer\"), Supernus Pharmaceuticals, Inc. (\"Parent\"), and Saphire, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the \"Closing Amount\"), plus (ii) one contingent value right (\"CVR\") per Share, each without interest and subject to the withholding of applicable taxes."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the \"Issuer\"), Supernus Pharmaceuticals, Inc. (\"Parent\"), and Saphire, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the \"Closing Amount\"), plus (ii) one contingent value right (\"CVR\") per Share, each without interest and subject to the withholding of applicable taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-100643","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2041689/000095017025100643/ownership.xml","form_type":"4"}},{"id":1101197,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":53916,"kind":"person","name":"Shiferman Gregory L.","position":1,"cik":"0002041689","reported_name":"Shiferman Gregory L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-06-26T20:02:20.000Z","date":"2025-06-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":79,"price":9.22,"value":728.38,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On June 24, 2025, the reporting person vested 234 shares of time-based restricted stock units (RSUs) granted on October 28, 2021 under the  Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vested 25% on September 24, 2022, and vests quarterly thereafter in twelve equal installments. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units."}],"balance_after":30950,"source":{"system":"sec-edgar","filing":"0001562180-25-005086","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2041689/000156218025005086/primarydocument.xml","form_type":"4"}},{"id":1173453,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":53916,"kind":"person","name":"Shiferman Gregory L.","position":1,"cik":"0002041689","reported_name":"Shiferman Gregory L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-04-11T20:09:32.000Z","date":"2025-04-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":176,"price":6.91,"value":1216.16,"ownership":{"direct":true},"balance_after":31029,"source":{"system":"sec-edgar","filing":"0001562180-25-003111","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2041689/000156218025003111/primarydocument.xml","form_type":"4"}},{"id":1173452,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":53916,"kind":"person","name":"Shiferman Gregory L.","position":1,"cik":"0002041689","reported_name":"Shiferman Gregory L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-04-11T20:09:32.000Z","date":"2025-04-10","kind":"grant","planned":false,"acquired":true,"shares":525,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 11, 2022, the reporting person was granted Performance Restricted Stock Units (PSUs) to acquire a total of 1,500 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on April 10, 2025, resulting in the vesting of the PSUs as to 525 shares."}],"balance_after":31205,"source":{"system":"sec-edgar","filing":"0001562180-25-003111","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2041689/000156218025003111/primarydocument.xml","form_type":"4"}},{"id":1191138,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":53916,"kind":"person","name":"Shiferman Gregory L.","position":1,"cik":"0002041689","reported_name":"Shiferman Gregory L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-03-26T20:36:43.000Z","date":"2025-03-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":79,"price":8.21,"value":648.59,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 24, 2025, the reporting person vested 235 shares of time-based restricted stock units (RSUs) granted on October 28, 2021 under the  Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vested 25% on September 24, 2022, and vests quarterly thereafter in twelve equal installments. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units."}],"balance_after":30680,"source":{"system":"sec-edgar","filing":"0001562180-25-002756","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2041689/000156218025002756/primarydocument.xml","form_type":"4"}},{"id":1246965,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":53916,"kind":"person","name":"Shiferman Gregory L.","position":1,"cik":"0002041689","reported_name":"Shiferman Gregory L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-02-25T21:54:54.000Z","date":"2025-02-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":2502,"price":7.49,"value":18739.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 24, 2025, the reporting person vested 7,500 shares of time-based restricted stock units (RSUs) granted on August 24, 2023 under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vested 100% on February 24, 2025. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units."}],"balance_after":30759,"source":{"system":"sec-edgar","filing":"0001562180-25-001614","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2041689/000156218025001614/primarydocument.xml","form_type":"4"}},{"id":1267769,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":53916,"kind":"person","name":"Shiferman Gregory L.","position":1,"cik":"0002041689","reported_name":"Shiferman Gregory L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-02-14T21:26:50.000Z","date":"2025-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":251,"price":7.18,"value":1802.18,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On February 13, 2025, the reporting person vested 750 shares of time-based restricted stock units (RSUs) granted on February 13, 2024 under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vests 25% on each grant anniversary date over four years. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units."}],"balance_after":33261,"source":{"system":"sec-edgar","filing":"0001562180-25-001200","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2041689/000156218025001200/primarydocument.xml","form_type":"4"}},{"id":1267768,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":53916,"kind":"person","name":"Shiferman Gregory L.","position":1,"cik":"0002041689","reported_name":"Shiferman Gregory L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-02-14T21:26:50.000Z","date":"2025-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":376,"price":7.18,"value":2699.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 13, 2025, the reporting person vested 1,125 shares of time-based restricted stock units (RSUs) granted on February 13, 2023 under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vests 25% on each grant anniversary date over four years. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units."}],"balance_after":33512,"source":{"system":"sec-edgar","filing":"0001562180-25-001200","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2041689/000156218025001200/primarydocument.xml","form_type":"4"}},{"id":1298935,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":53916,"kind":"person","name":"Shiferman Gregory L.","position":1,"cik":"0002041689","reported_name":"Shiferman Gregory L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2025-01-21T21:12:00.000Z","date":"2025-01-16","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The securities awarded on January 16, 2025 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan. Options to purchase 7,000 shares of common stock shall vest on the one year anniversary of January 16, 2025, with 21,000 shares vesting in 36 equal monthly installments thereafter."}],"balance_after":28000,"derivative":{"exercise_price":6.97,"expiration_date":"2035-01-16","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001562180-25-000438","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2041689/000156218025000438/primarydocument.xml","form_type":"4"}},{"id":1298934,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":53916,"kind":"person","name":"Shiferman Gregory L.","position":1,"cik":"0002041689","reported_name":"Shiferman Gregory L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-01-21T21:12:00.000Z","date":"2025-01-16","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of common stock issuable under 14,000 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on January 16, 2026."}],"balance_after":33888,"source":{"system":"sec-edgar","filing":"0001562180-25-000438","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2041689/000156218025000438/primarydocument.xml","form_type":"4"}},{"id":1321078,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":53916,"kind":"person","name":"Shiferman Gregory L.","position":1,"cik":"0002041689","reported_name":"Shiferman Gregory L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-12-27T21:11:56.000Z","date":"2024-12-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":79,"price":5.48,"value":432.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 24, 2024, the reporting person vested 235 shares of time-based restricted stock units (RSUs) granted on October 28, 2021 under the  Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vested 25% on September 24, 2022, and quarterly thereafter in twelve equal installments. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units."}],"balance_after":19888,"source":{"system":"sec-edgar","filing":"0001562180-24-008597","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2041689/000156218024008597/primarydocument.xml","form_type":"4"}},{"id":1378321,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":53916,"kind":"person","name":"Shiferman Gregory L.","position":1,"cik":"0002041689","reported_name":"Shiferman Gregory L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2024-11-01T20:24:22.000Z","date":"2024-11-01","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on November 1, 2024, pursuant to the Plan. The shares underlying the option vest over four years, with 25% of the shares vesting on November 1, 2025, and the remainder vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service."}],"balance_after":10000,"derivative":{"exercise_price":6.05,"expiration_date":"2034-10-31","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-24-007490","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2041689/000156218024007490/primarydocument.xml","form_type":"4"}},{"id":1378320,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":53916,"kind":"person","name":"Shiferman Gregory L.","position":1,"cik":"0002041689","reported_name":"Shiferman Gregory L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-11-01T20:24:22.000Z","date":"2024-11-01","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 5,000 restricted stock units (\"RSUs\") awarded to the Reporting Person pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan (the \"Plan\"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on November 1, 2025, subject to the Reporting Person's continued service."}],"balance_after":19967,"source":{"system":"sec-edgar","filing":"0001562180-24-007490","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2041689/000156218024007490/primarydocument.xml","form_type":"4"}}]}